Results 31 to 40 of about 16,658,609 (280)

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development.

, 2023
CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, and clinical response. Prolonged ex vivo culturing is known to deplete Tstem, affecting clinical outcome.
Davis, Jaclyn, Engels, Boris, Quinn, David, Shah, Nirav N., Treanor, Louise, Price, Andrew, Sohoni, Akash Kamalakar, Mataraza, Jennifer, Briones, Javier, Shune, Leyla, Zhu, Xu, Moschetta, Michele, Bondanza, Attilio, Marchal, Anne-Laure, Yang, Jennifer, Barba, Pere, Orlando, Elena, Blaise, Didier, Lu, Darlene, Mariconti, Luisa, Xu, Zhu, Flinn, Ian, Brogdon, Jennifer, Boissel, Nicolas, de Parseval, Laure, Jäger, Ulrich, Dickinson, Michael   +26 more
core   +1 more source

CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead

Journal of Immunology Research, 2020
Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. Like other technologies, CAR-T cell therapy has undergone a long development process, and persistent explorations of the ...
Qingyang Zhang, Jieming Ping, Zirui Huang, Xiaoli Zhang, Jingyi Zhou, Gangyang Wang, Shaoyang Liu, Jianjun Ma   +7 more
doaj   +1 more source

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy

Frontiers in Immunology, 2023
Patient-derived autologous chimeric antigen receptor (CAR)-T cell therapy is a revolutionary breakthrough in immunotherapy and has made impressive progress in both preclinical and clinical studies.
Zixin Lv, Zixin Lv, Feifei Luo, Feifei Luo, Yiwei Chu, Yiwei Chu   +5 more
doaj   +1 more source

CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited.
Van To, Van To, Van To, Vera J. Evtimov, Graham Jenkin, Graham Jenkin, Graham Jenkin, Aleta Pupovac, Alan O. Trounson, Alan O. Trounson, Alan O. Trounson, Richard L. Boyd   +11 more
doaj   +1 more source

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice

eJHaem, 2022
In recent years, we have seen rapid expansion of chimeric antigen receptor T‐cell (CAR‐T) therapies in multiple malignancies. CAR‐T therapy has profoundly altered the treatment landscape of non‐Hodgkin lymphoma, B‐cell acute lymphoblastic leukemia, and ...
Salyka Sengsayadeth, Bipin N. Savani, Olalekan Oluwole, Bhagirathbhai Dholaria   +3 more
doaj   +1 more source

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks [PDF]

, 2023
CAR T cell-based therapies have revolutionized the treatment of hematological malignancies such as leukemia and lymphoma within the last years. In contrast to the success in hematological cancers, the treatment of solid tumors with CAR T cells is still a
Daniel M. Aebersold, Hovhannisyan, Lusine, Riether, Carsten, Medova, Michaela, Aebersold, Daniel M, Lusine Hovhannisyan, Carsten Riether, Yitzhak Zimmer, Michaela Medová, Zimmer, Yitzhak   +9 more
core   +2 more sources

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of certain hematological malignancies. While CAR-T cells have produced robust responses in certain hematological malignancies, toxicities associated with the therapy ...
Robert C. Sterner, Rosalie M. Sterner
doaj   +1 more source

Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer

Advanced Science, 2020
Growing experience with engineered chimeric antigen receptor (CAR)‐T cells has revealed some of the challenges associated with developing patient‐specific therapy.
Ahmed M. E. Abdalla, Lin Xiao, Yu Miao, Lixia Huang, Gendeal M. Fadlallah, Mario Gauthier, Chenxi Ouyang, Guang Yang   +7 more
doaj   +1 more source

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell leukemia or lymphoma. Unfortunately, many challenges remain to be addressed
Manasi P. Jogalekar, Ramya Lakshmi Rajendran, Fatima Khan, Crismita Dmello, Prakash Gangadaran, Prakash Gangadaran, Byeong-Cheol Ahn, Byeong-Cheol Ahn   +7 more
doaj   +1 more source

Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma

, 2023
Tingyu Liang,* Yixuan Song,* Lingui Gu, Yu Wang, Wenbin Ma Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China*These ...
Liang T, Gu L, Wang Y, Song Y, Ma W
core